...
首页> 外文期刊>Journal of endovascular therapy: an official journal of the International Society of Endovascular Specialists >Paclitaxel-eluting balloon vs. standard angioplasty to reduce recurrent restenosis in diabetic patients with in-stent restenosis of the superficial femoral and proximal popliteal arteries: The DEBATE-ISR study
【24h】

Paclitaxel-eluting balloon vs. standard angioplasty to reduce recurrent restenosis in diabetic patients with in-stent restenosis of the superficial femoral and proximal popliteal arteries: The DEBATE-ISR study

机译:紫杉醇洗脱球囊与标准血管成形术可减少糖尿病患者股浅及fe部近端支架内再狭窄的再狭窄:DEBATE-ISR研究

获取原文
获取原文并翻译 | 示例
           

摘要

Purpose: To test the ability of a drug-eluting balloon (DEB) to reduce recurrent in-stent restenosis (ISR) in diabetic patients with femoropopliteal stents. Methods: A prospective all-comers study [Drug-Eluting Balloon in Peripheral Intervention for In-Stent Restenosis (DEBATE-ISR); ClinicalTrials.gov identifier NCT01558531] of symptomatic diabetic patients with femoropopliteal ISR undergoing treatment with paclitaxel-eluting balloons was designed to compare their 12-month recurrent restenosis rate with that of historical diabetic controls. From January 2010 to December 2011, 44 consecutive diabetic patients (32 men; mean age 74±11 years) were treated with DEBs and enrolled in the study. The control group comprised 42 diabetic patients (23 men; mean age 76±7 years) treated with a conventional balloon for femoropopliteal ISR from 2008 to 2009. Results: No significant differences in terms of clinical, angiographic, or procedural characteristics were observed between the study groups. Lesion length was 132±86 mm in the DEB group vs. 137±82 mm in the BA group. Procedural success, defined as a residual stenosis <30% in the restenotic segment (stent +5 mm at proximal and distal edges), was obtained in all treated lesions. At 1-year follow-up, 6 patients died (3 in each group), and 1 patient in the BA group underwent major amputation. Recurrent restenosis, assessed by angiography (66%) or ultrasound (34%), occurred in 8/41 (19.5%) patients in the DEB group vs. 28/39 (71.8%) in the BA group (p<0.001). Target lesion revascularization for symptomatic recurrent restenosis was performed in 6/44 (13.6%) patients in the DEB vs.13/42 (31.0%) in the BA group (p=0.045). Conclusion: Using DEB for treating femoropopliteal ISR led to a significant reduction in recurrent restenosis and repeat angioplasty at 1-year follow-up as compared to historical controls.
机译:目的:测试药物洗脱球囊(DEB)减少患有股pop支架的糖尿病患者复发性支架内再狭窄(ISR)的能力。方法:一项前瞻性的前瞻性研究[药物洗脱球囊在支架内再狭窄的外周介入治疗中的作用(DEBATE-ISR);设计有症状的接受pop紫杉醇洗脱球囊治疗的股popISR的有症状糖尿病患者,将其12个月的复发性再狭窄率与历史糖尿病对照进行比较。从2010年1月至2011年12月,接受DEB治疗的44例连续糖尿病患者(32例男性,平均年龄74±11岁)并参加了研究。对照组包括2008年至2009年用常规气囊治疗股pop ISR的42例糖尿病患者(23例男性,平均年龄76±7岁)。结果:两组之间在临床,血管造影或手术方面均无显着差异。学习小组。 DEB组的病变长度为132±86 mm,而BA组的为137±82 mm。在所有治疗的病变中均获得了成功的手术定义为残余狭窄<30%(在再狭窄部分(支架近端和远端边缘+5 mm))。在1年的随访中,有6例患者死亡(每组3例),BA组中有1例患者接受了大截肢术。通过血管造影(66%)或超声(34%)评估的复发性再狭窄发生在DEB组的8/41(19.5%)患者中,而BA组的发生在28/39(71.8%)患者(p <0.001)。 DEB的有症状复发性再狭窄的目标病变血运重建在6/44(13.6%)患者中进行,而BA组则为13/42(31.0%)(p = 0.045)。结论:与历史对照相比,使用DEB治疗股pop ISR可显着减少复发性再狭窄和1年随访时的重复血管成形术。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号